Hence, multiple Tyk2 inhibitors are being evaluated for the treatment of inflammatory diseases such as psoriasis, psoriatic arthritis, hidradenitis suppurativa, inflammatory bowel disease, dermatomyositis, and SLE [10,29,30]. This evidence concerns the gene TYK2 and psoriatic arthritis.